Tumor Mutation Burden and Differentially Mutated Genes Among Immune Phenotypes in Patients with Lung Adenocarcinoma

INTRODUCTION: Nowadays, immune checkpoint blockades (ICBs) have been extensively applied in non-small cell lung cancer (NSCLC) treatment. However, the outcome of anti-program death-1/program death ligand-1 (anti-PD-1/PD-L1) therapy is not satisfying in EGFR-mutant lung adenocarcinoma (LUAD) patients...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Onco Targets Ther
Autors principals: Wang, Hao, Chen, Shanhao, Meng, Die, Wu, Chunyan, Zhu, Junjie, Jiang, Minlin, Ning, Jing, Wu, Shengyu, Wu, Lijia, Li, Jingjie, Chen, Bin, Zhao, Sha, Li, Wei, Yu, Jia, Fang, Qiyu, Zhu, Jun, Zhao, Wencheng, He, Yayi, Zhou, Caicun
Format: Artigo
Idioma:Inglês
Publicat: Dove 2021
Matèries:
Original Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC8106479/
https://ncbi.nlm.nih.gov/pubmed/33976553
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S294993
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars